AIM:To study the therapeutic effect of visual occlusion combined with levodopa and benserazide hydrochloride tables on children with amblyopia.

METHODS: Totally 90 cases(140 eyes)of children diagnosed with amblyopia in our hospital were selected from January 2016 to January 2017. They were randomly divided into the monotherapy group and the combined treatment group, and 35 healthy children(70 eyes)were selected as the normal group for comparison. Patients in the monotherapy group were treated with visual cover, while patients in the combined treatment group were treated with oral administration of levodopa and benserazide tablets on the basis of visual cover. Tears were extracted from both groups of children before and after treatment, and the protein levels of CREB and PKA in tears of 140 eyes and 70 eyes of children in the normal group were detected by enzyme-linked immunosorbent assay. The index levels of the two groups and the normal group were compared, as well as the therapeutic efficiency of different age groups and the total therapeutic efficiency of different methods.

RESULTS: After treatment, the levels of IL-1β, IL-6 and IL-9 in the combined treatment group were significantly lower than those in the single treatment group after treatment(P<0.05).After treatment, the levels of CREB and PKA in the combined treatment group were significantly lower than those in the single treatment group(P<0.05).The total effective rate of children at the age of 3-6 in the combined treatment group and the single treatment group was significantly higher than those at the age of 7-9 and 10-12 in each group(P<0.05). The total therapeutic efficiency of the combined treatment group was significantly higher than that of the single treatment group, and the difference was statistically significant(P<0.05).

CONCLUSION: Combined with the traditional masking method, levodopa and benserazide hydrochloride tables can improve the treatment of children's amblyopia. The earlier the treatment time, the better and the higher efficiency is.